Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

2.1K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.1K
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

28
Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
28
Hepatitis01:25

Hepatitis

86
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
86
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

42
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to...
42
Gallbladder01:17

Gallbladder

3.2K
The gallbladder is a small, pear-shaped organ that plays a crucial role in our digestive system. Measuring about 10 cm in length, it is comparable in size to a kiwi fruit and is located in a hollow area on the lower surface of the liver. The gallbladder's primary function is to store and concentrate bile, a fluid produced by the liver that aids in digestion.
The gallbladder's anatomy consists of three regions: the fundus, body, and neck. Extending from the neck, the cystic duct joins...
3.2K
Liver Physiology01:30

Liver Physiology

3.8K
The liver, an essential organ in the human body, performs over 200 vital functions that can be broadly categorized into metabolic, hematological, endocrine regulation, and bile production.
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of  70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can...
3.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Addressing Obstetric and Gynecologic Needs in Thalassemia.

O&G open·2026
Same author

Real-world safety profile of twice a day deferiprone in patients with thalassemia, sickle cell disease, or other anemias.

Blood advances·2026
Same author

Chronic Anemia Patients Demonstrate Diffuse Demyelination.

American journal of hematology·2026
Same author

Immunosuppressive therapy for severe aplastic anemia in children under the age of 3 years yields a high response rate: a North American collaborative study.

Haematologica·2026
Same author

Wearable Device Photoplethysmography As a Viable Tool to Longitudinally Monitor Vasoconstriction Biomarkers for Predicting Vaso-Occlusive Crisis in Sickle Cell Disease: Feasibility and Validation Study.

JMIR human factors·2026
Same author

From treatment to biology and back: managing iron overload in transfused hemoglobinopathies.

Hematology. American Society of Hematology. Education Program·2025

Related Experiment Video

Updated: May 2, 2026

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis
08:56

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis

Published on: February 10, 2015

56.5K

Bad liver and a broken heart.

Thomas D Coates1

  • 1CHILDREN'S HOSPITAL LOS ANGELES;

Blood
|March 15, 2014
PubMed
Summary

Deferasirox is as effective as deferoxamine for reducing cardiac iron in beta-thalassemia patients. Lowering liver iron concentration improves the effectiveness of iron removal therapies.

Area of Science:

  • Hematology
  • Cardiology
  • Pharmacology

Background:

  • Beta-thalassemia patients often experience iron overload due to frequent blood transfusions.
  • Cardiac iron accumulation is a major cause of morbidity and mortality in beta-thalassemia.
  • Iron chelation therapy is essential for managing iron overload.

Purpose of the Study:

  • To compare the efficacy of deferasirox (DFX) versus deferoxamine (DFO) in removing cardiac iron.
  • To assess the impact of liver iron concentration (LIC) on iron removal efficacy.

Main Methods:

  • The CORDELIA study involved patients with beta-thalassemia and cardiac iron.
  • Cardiac iron was assessed, and patients received either DFX or DFO.
  • Liver iron concentration (LIC) was measured.

More Related Videos

A Mouse Model of Chronic Liver Fibrosis for the Study of Biliary Atresia
09:12

A Mouse Model of Chronic Liver Fibrosis for the Study of Biliary Atresia

Published on: February 3, 2023

5.2K
Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
09:44

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Published on: November 27, 2019

10.7K

Related Experiment Videos

Last Updated: May 2, 2026

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis
08:56

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis

Published on: February 10, 2015

56.5K
A Mouse Model of Chronic Liver Fibrosis for the Study of Biliary Atresia
09:12

A Mouse Model of Chronic Liver Fibrosis for the Study of Biliary Atresia

Published on: February 3, 2023

5.2K
Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
09:44

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Published on: November 27, 2019

10.7K

Main Results:

  • Deferasirox (DFX) was found to be non-inferior to deferoxamine (DFO) in reducing cardiac iron.
  • The study confirmed that lower liver iron concentration (LIC) is associated with more effective cardiac iron removal.
  • Both chelators demonstrated efficacy in iron reduction.

Conclusions:

  • Deferasirox is a viable alternative to deferoxamine for cardiac iron chelation in beta-thalassemia.
  • Optimizing liver iron levels may enhance the effectiveness of iron chelation therapy for cardiac iron reduction.